TIL

Instil Bio, Inc. (NASDAQ:TIL) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dallas, Texas. The company went public in March 2021 and focuses on developing innovative cell therapies for cancer treatment. Instil Bio specializes in tumor infiltrating lymphocyte (TIL) therapy, a form of immunotherapy that harnesses the body's own immune system to fight cancer. As a clinical-stage company, Instil Bio has no approved products on the market and is currently conducting clinical trials to demonstrate the safety and efficacy of its therapeutic candidates.